Serum osteocalcin, total alkaline phosphatase, intact parathyroid hormone (PTH), creatinine, calcium, and phosphate were determined in 23 kidney cadaveric allograft recipients, immediately before and 0·5, 1, 3 and 6 months after surgery. Immunosuppressive treatment was based on low doses of corticosteroids and cyclosporin combined with antilymphoblast globulin. The decrease in serum creatinine was accompanied by falling PTH concentrations. Serum osteocalcin levels were higher than normal before kidney transplantation and diminished at 0·5 and 1 month after surgery. Significant increases in serum osteocalcin concentrations were observed 3 and 6 months after kidney transplantation with a significant correlation with alkaline phosphatase levels. The increase in serum osteocalcin levels observed in our transplanted patients is not related with a parallel increase in serum creatinine levels nor with an increment in PTH levels; it seems to reflect an increase in the osteoblastic activity, which is not altered by steroid therapy.
GarneroPGrimauxMSeguinPDelmasPD. Characterization of immunoreactive forms of human osteocalcin generated in vivo andin vitro. J Bone Mineral Res1994; 9: 255–64.
2.
WorsfoldMSharpCADavieMWJ. Serum osteocalcin and other indices of bone formation: An 8-decade population study in healthy men and women. Clin Chim Acta1988; 178: 225–36.
3.
MallucheHHFaugereMCFantiPPricePA. Plasma levels of bone gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int1984; 26: 869–74.
4.
GundbergCMWeinsteinRS. Muliple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest1986; 77: 1762–7.
5.
EpsteinSTrabergHRajaRPoserJ. Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab1985; 60: 1253–6.
6.
GonzalezMTGonzalezCGriñóJMCastelaoAMMariñosoMLSerranoS. Long-term evolution of renal osteodystrophy after kidney transplantation: Comparative study between intact PTH levels and bone biopsy. Transplant Proc1990; 22: 1407–11.
7.
TaylorAKLuekenSALibanatiCBaylinkDJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Clin N Am1994; 20: 589–606.
8.
BoiskinIEpsteinSIsmailFThomasSBRajaR. Serum osteocalcin and bone mineral metabolism following successful renal transplantation. Clin Nephrol1989; 31: 316–22.
9.
BonninMRGonzalezMTHuguetJGuillenENavarroMA. Serum osteocalcin levels in patients after kidney transplantation. Clin Nephrol1990; 3: 255.
10.
GundbergCMWilsonPSGallopPMParfittAM. Determination of osteocalcin in human serum: Results with two kits compared with those by a well characterized assay. Clin Chem1985; 34: 1720–3.
11.
LukertandBPRaiszLG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Int Med1990; 112: 352–64.
12.
KaspersenHCharlesPMosekildeL. The effect of single oral doses of predisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab1988; 67: 1025–30.
13.
GriñoJMAlsinaJSabaterRCastelaoAMGil-VernetSAndresE. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Transplantation1990; 49: 1114–7.
14.
GriñoJMCastelaoAMSeronDGonzalezCGalceranJMGil-VernetS. Antilymphocyte Globulin versus OKT3 induction therapy in cadaveric kidney transplantation: A prospective randomized study. Am J Kidney Dis1992; 20: 603–10.
15.
BonninMRGonzalezMTArranzBRoselPNavarroMA. Intact parathyrin in patients after kidney transplantation. Clin Chem1988; 34: 2378.
ChazanJALibbeyNPLondonMRPonoLAbueloJG. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: A correlation between biochemical parameters and bone pathology findings. Clin Nephrol1991; 35: 78–85.
18.
SlatopolskyEDelmezJ. Bone disease in chronic renal failure and after renal transplantation. In: Disorders of Bone and Mineral Metabolism. CoeFLFabusJ, eds. Raven Press, 1992.
19.
AlsinaJGonzalezMTBonninMRRicartYCastelaoAMGonzalezC. Long-term evolution of renal osteodystrophy after renal transplantation. Transplant Proc1989; 21: 2151–8.
20.
DempsterDW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Min Res1989; 4: 137–41.
21.
PrummerMWiersingaWMLipsPSandersGTBSaurweinHP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab1991; 72: 382–6.
22.
GonzalezMTGonzalezCBoverJBonninMRMariñosoMLSerranoS. Does immuno-suppressive therapy influence the recovery of bone disease in kidney transplant recipients?Transplant Proc1992; 24: 99–102.
23.
CharhonSADelmasPDMalavalLChavassieuxPMArlotMChapuyMC. Serum bone gla-protein in renal osteodystrophy: Comparison with bone histomorphometry. J Clin Endocrinol Metab1986; 63: 892–7.
24.
DudaRJJO'BrienJFKatzmannJAPetersonJMMannKGRiggsBL. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase; effects of sex, age and metabolic bone disease. J Clin Endocrinol Metab1988; 66: 951–7.
25.
KaspersenHThomsenKEricsenEFCharlesPStormTMosekildeL. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Min1988; 4: 105–13.
26.
AmadoJARianchoJAde FranciscoALMCotorrueloJGFeijenesJAriasM. Hyperparathyroidism is responsible for the increased levels of osteocalcin in patients with normally functioning kidney grafts. Nephron1989; 52: 209–15.
